Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway (Q39680200)
Jump to navigation
Jump to search
scientific article published on 14 July 2010
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway |
scientific article published on 14 July 2010 |
Statements
1 reference
Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway (English)
1 reference
Dieter Häussinger
1 reference
Paul Dent
1 reference
Sarah Spiegel
1 reference
Margaret A Park
1 reference
Clint Mitchell
1 reference
Guo Zhang
1 reference
Adly Yacoub
1 reference
Jeremy Allegood
1 reference
Roland Reinehr
1 reference
Andrew Larner
1 reference
Paul B Fisher
1 reference
Christina Voelkel-Johnson
1 reference
Besim Ogretmen
1 reference
Steven Grant
1 reference
14 July 2010
1 reference
1 reference
70
1 reference
15
1 reference
6313-6324
1 reference
Identifiers
1 reference
1 reference
1 reference